Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1991 Dec;74(4):719–724.

Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.

T Seya 1, M Okada 1, T Hara 1, M Matsumoto 1, S Miyagawa 1, M Oshimura 1
PMCID: PMC1384786  PMID: 1723716

Abstract

The structural genes of human complement regulatory proteins are clustered on chromosome 1 at position q3.2. Human chromosome 1 was transferred into a mouse fibroblast cell line, A9 [designated as A9(neo-1)], and the surface expression of its gene products participating in complement regulation, namely C3b/C4b receptor (CR1, CD35), decay-accelerating factor (DAF, CD55), membrane co-factor protein (MCP, CD46) and C3d/EB virus receptor (CR2, CD21), were assessed using respective monoclonal antibodies by flow cytometry. CR1 became positive within 7 days of culture. MCP appeared in a small population of cells by Day 3 and, together with DAF, began to increase on Day 7. CR2 appeared on Day 14. The order of the expression was CR1 greater than DAF = MCP greater than CR2. On Day 42, however, all became negative except for MCP, which was markedly diminished. These human regulatory proteins were specifically associated with the presence of human chromosome 1, since none of them were expressed on human chromosome 12-transferred A9 cells [A9(neo-12)]. Intact A9 and A9(neo-12) cells activated human complement via the alternative pathway. The activation of this pathway was suppressed in the A9(neo-1) cells that expressed CR1, DAF and MCP. Slight protective activity was still observed in the 42-day cultured A9(neo-1) cells expressing only trace MCP. These results suggest that human complement regulators, expressed via the transferred human chromosome 1, can protect heterologous cells from complement, overcoming their ability to activate the human alternative pathway.

Full text

PDF
719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaout M. A., Colten H. R. Complement C3 receptors: structure and function. Mol Immunol. 1984 Dec;21(12):1191–1199. doi: 10.1016/0161-5890(84)90009-9. [DOI] [PubMed] [Google Scholar]
  2. Caudwell V., Porteu F., Calender A., Pangburn M. K., Halbwachs-Mecarelli L. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines. Eur J Immunol. 1990 Dec;20(12):2643–2650. doi: 10.1002/eji.1830201218. [DOI] [PubMed] [Google Scholar]
  3. Fearon D. T. Activation of the alternative complement pathway. CRC Crit Rev Immunol. 1979 Nov;1(1):1–32. [PubMed] [Google Scholar]
  4. Fischer E., Kazatchkine M. D. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. J Immunol. 1983 Jun;130(6):2821–2824. [PubMed] [Google Scholar]
  5. Hourcade D., Holers V. M., Atkinson J. P. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381–416. doi: 10.1016/s0065-2776(08)60697-5. [DOI] [PubMed] [Google Scholar]
  6. Kameyoshi Y., Matsushita M., Okada H. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase. Immunology. 1989 Dec;68(4):439–444. [PMC free article] [PubMed] [Google Scholar]
  7. Kinoshita T., Lavoie S., Nussenzweig V. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1). J Immunol. 1985 Apr;134(4):2564–2570. [PubMed] [Google Scholar]
  8. Kinoshita T., Medof M. E., Silber R., Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1985 Jul 1;162(1):75–92. doi: 10.1084/jem.162.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Koi M., Morita H., Shimizu M., Oshimura M. Construction of mouse A9 clones containing a single human chromosome (X/autosome translocation) via micro-cell fusion. Jpn J Cancer Res. 1989 Feb;80(2):122–125. doi: 10.1111/j.1349-7006.1989.tb02278.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koi M., Shimizu M., Morita H., Yamada H., Oshimura M. Construction of mouse A9 clones containing a single human chromosome tagged with neomycin-resistance gene via microcell fusion. Jpn J Cancer Res. 1989 May;80(5):413–418. doi: 10.1111/j.1349-7006.1989.tb02329.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lublin D. M., Coyne K. E. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med. 1991 Jul 1;174(1):35–44. doi: 10.1084/jem.174.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Matsumoto M., Sugita Y., Seya T. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis. Eur J Immunol. 1991 Aug;21(8):1787–1792. doi: 10.1002/eji.1830210802. [DOI] [PubMed] [Google Scholar]
  13. Medof M. E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984 Nov 1;160(5):1558–1578. doi: 10.1084/jem.160.5.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Miyagawa S., Hirose H., Shirakura R., Naka Y., Nakata S., Kawashima Y., Seya T., Matsumoto M., Uenaka A., Kitamura H. The mechanism of discordant xenograft rejection. Transplantation. 1988 Dec;46(6):825–830. doi: 10.1097/00007890-198812000-00007. [DOI] [PubMed] [Google Scholar]
  15. Mold C., Nemerow G. R., Bradt B. M., Cooper N. R. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol. 1988 Mar 15;140(6):1923–1929. [PubMed] [Google Scholar]
  16. Nemerow G. R., Wolfert R., McNaughton M. E., Cooper N. R. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol. 1985 Aug;55(2):347–351. doi: 10.1128/jvi.55.2.347-351.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pangburn M. K., Müller-Eberhard H. J. The alternative pathway of complement. Springer Semin Immunopathol. 1984;7(2-3):163–192. doi: 10.1007/BF01893019. [DOI] [PubMed] [Google Scholar]
  18. Ross G. D., Medof M. E. Membrane complement receptors specific for bound fragments of C3. Adv Immunol. 1985;37:217–267. doi: 10.1016/s0065-2776(08)60341-7. [DOI] [PubMed] [Google Scholar]
  19. Seya T., Hara T., Matsumoto M., Akedo H. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol. 1990 Jul 1;145(1):238–245. [PubMed] [Google Scholar]
  20. Seya T., Hara T., Matsumoto M., Sugita Y., Akedo H. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46). J Exp Med. 1990 Dec 1;172(6):1673–1680. doi: 10.1084/jem.172.6.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Seya T., Hara T., Uenaka A., Nakayama E., Akedo H. Application of protein A-rosette assay for screening of monoclonal antibodies to human complement regulatory proteins. Complement Inflamm. 1990;7(2):78–89. doi: 10.1159/000463132. [DOI] [PubMed] [Google Scholar]
  22. Seya T., Holers V. M., Atkinson J. P. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J Immunol. 1985 Oct;135(4):2661–2667. [PubMed] [Google Scholar]
  23. Wong W. W., Fearon D. T. p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. J Immunol. 1985 Jun;134(6):4048–4056. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES